E
88.29
1.07 (1.23%)
| Previous Close | 87.22 |
| Open | 87.73 |
| Volume | 1,795,549 |
| Avg. Volume (3M) | 3,700,326 |
| Market Cap | 50,890,354,688 |
| Price / Earnings (TTM) | 52.55 |
| Price / Earnings (Forward) | 25.64 |
| Price / Sales | 7.75 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Mixed | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Relative Valuation | -5.0 |
| Financial Health | 5.0 |
| AI Insight | NA |
| Weighted Average | 1.00 |
Select this tab to load the latest available analysis.
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 30 Jun 2026 | 13,002,965 |
| Ninety One Uk Ltd | 30 Sep 2026 | 11,943,675 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIPPIS DANIEL J. | - | 84.24 | -619 | -52,145 |
| Aggregate Net Quantity | -619 | |||
| Aggregate Net Value ($) | -52,145 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 84.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIPPIS DANIEL J. | Officer | 08 Oct 2026 | Automatic sell (-) | 619 | 84.24 | 52,145 |
| LIPPIS DANIEL J. | Officer | 08 Oct 2026 | Option execute | 619 | - | - |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |